Table 1.
The characteristics of patients with EOC.
| EOC patients | Chinese |
Germany |
Total |
|---|---|---|---|
| 75 (100%) | 90 (100%) | 165 (100%) | |
| Age (median) | 62 (25-84 years) | 63 (30-89 years) | 62 (25-89 years) |
| Follow-up time (median) | 14 (1-38 months) | 18 (1-77 months) | 16 (1-77 months) |
| Histology | |||
| Serious | 41 (54.7%) | 74 (82.3%) | 115 (69.7%) |
| Endometrial | 9 (12.0%) | 10 (11.1%) | 19 (11.5%) |
| Other subtypes | 11 (14.7%) | 3 (3.3%) | 14 (8.5%) |
| Unknown | 14 (18.6%) | 3 (3.3%) | 17 (10.3%) |
| FIGO stage | |||
| I | 12 (16.0%) | 18 (20.0%) | 30 (18.2%) |
| II | 15 (20.0%) | 5 (5.5%) | 20 (12.1%) |
| III | 27 (36.0%) | 51 (56.7%) | 78 (47.3%) |
| IV | 21 (28.0%) | 15 (16.7%) | 36 (21.8%) |
| Unknown | 0 (0.0%) | 1 (1.1%) | 1 (0.6%) |
| Lymph node status | |||
| N0 | 30 (40.0%) | 27 (30.0%) | 57 (34.5%) |
| N1 | 36 (48.0%) | 45 (50.0%) | 81 (49.1%) |
| Unknown | 9 (12.0%) | 18 (20.0%) | 27 (16.4%) |
| Grading | |||
| G1-2 | 18 (24.0%) | 29 (32.2%) | 47 (28.5%) |
| G3 | 37 (49.3%) | 58 (64.4%) | 95 (57.6%) |
| Unknown | 20 (26.7%) | 3 (3.4%) | 23 (13.9%) |
| Postoperative tumor residue | |||
| Tumor free | 45 (60.0%) | 59 (65.5%) | 104 (63.0%) |
| < 1 cm | 25 (33.3%) | 15 (16.7%) | 40 (24.2%) |
| > 1 cm | 5 (6.7%) | 9 (10.0%) | 14 (8.5%) |
| Unknown | 0 (0.0%) | 7 (7.8%) | 7 (4.3%) |
| Survival status | |||
| Dead | 19 (25.3%) | 26 (28.9%) | 45 (27.3%) |
| Alive | 47 (62.7%) | 54 (60.0%) | 101 (61.2%) |
| Unknown | 9 (12.0%) | 10 (11.1%) | 19 (11.5%) |
| Recurrent status | |||
| Yes | 2 (2.7%) | 37 (41.1%) | 39 (23.6%) |
| No | 3 (4.0%) | 47 (52.2%) | 50 (30.3%) |
| Unknown | 70 (93.3%) | 6 (6.7%) | 76 (46.1%) |
| CA125 (U/mL) | |||
| <65 | 17 (22.7%) | 11 (12.2%) | 28 (17.0%) |
| ≥65 | 58 (77.3%) | 65 (72.2%) | 123 (74.5%) |
| Unknown | 0 (0.0%) | 14 (15.6%) | 14 (8.5%) |